Fulcrum Therapeutics Expects $240 Million Cash Position as of December 31, 2024

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) recently provided an update on its financial situation through an updated corporate presentation published on its website on January 13, 2025. While the comprehensive financial results for the fourth quarter and fiscal year ending December 31, 2024, are yet to be finalized, the company anticipates reporting approximately $240 million in […]

Leave a Reply

Your email address will not be published.

Previous post Mplx Lp (NYSE:MPLX) Sees Large Decrease in Short Interest
Next post TMC the metals Sees Unusually High Options Volume (NASDAQ:TMC)